Lipocine (STU:2VT0) Change In Payables And Accrued Expense : €-0.45 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Lipocine Change In Payables And Accrued Expense?

Lipocine's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €-1.09 Mil. It means Lipocine's Accounts Payable & Accrued Expense declined by €1.09 Mil from Dec. 2023 to Mar. 2024 .

Lipocine's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €0.86 Mil. It means Lipocine's Accounts Payable & Accrued Expense increased by €0.86 Mil from Dec. 2022 to Dec. 2023 .

Lipocine Change In Payables And Accrued Expense Historical Data

The historical data trend for Lipocine's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Change In Payables And Accrued Expense Chart

Lipocine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.43

1.33

-0.84

-0.59

0.86

Lipocine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.24	-0.10	0.39	0.34	-1.09

Lipocine Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.45 Mil.

Lipocine Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Lipocine's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipocine (STU:2VT0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (STU:2VT0) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

LPCN:USA

Address

675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108

Website

http://www.lipocine.com

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.

Lipocine (STU:2VT0) Headlines

No Headlines